Publications (36) MANUEL ALEIXANDRE RICO publications

2022

  1. Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil

    Journal of Alzheimer's disease : JAD, Vol. 90, Núm. 2, pp. 705-717

2021

  1. Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin plus Donepezil in Patients with Advanced Alzheimer's Disease

    International Journal of Neuropsychopharmacology, Vol. 23, Núm. 9, pp. 581-586

2018

  1. Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 Carriers

    Journal of Alzheimer's Disease, Vol. 63, Núm. 3, pp. 1003-1013

  2. Una Psicología para el siglo XXI: libro de resúmenes : Almería, 19 al 21 abril 2018 dir.

    Universidad de Almería

2016

  1. Synergistic increase of serum BDNF in Alzheimer patients treated with cerebrolysin and donepezil: Association with cognitive improvement in apoe4 cases

    International Journal of Neuropsychopharmacology, Vol. 19, Núm. 6, pp. 1-6

2014

  1. Apathy and APOE4 are associated with reduced BDNF levels in alzheimer's disease

    Journal of Alzheimer's Disease, Vol. 42, Núm. 4, pp. 1347-1355

2011

  1. Combination treatment in Alzheimer's disease: Results of a randomized, controlled trial with cerebrolysin and donepezil

    Current Alzheimer Research, Vol. 8, Núm. 5, pp. 583-591

  2. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: Results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

    European Journal of Neurology, Vol. 18, Núm. 1, pp. 59-68

2009

  1. Reduced TNF- and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent Cerebrolysin

    International Journal of Neuropsychopharmacology, Vol. 12, Núm. 7, pp. 867-872

2008

  1. Death anxiety in institutionalized and non-institutionalized elderly people in Spain

    Omega: Journal of Death and Dying, Vol. 58, Núm. 1, pp. 61-76

2007

  1. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease

    Neurobiology of Aging, Vol. 28, Núm. 4, pp. 533-536

2006

  1. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

    European Journal of Neurology, Vol. 13, Núm. 1, pp. 43-54

2004

  1. Introducción a la psicogerontología

    Pirámide

2003

  1. La medición de la capacidad funcional en el mayor desde la perspectiva de los apoyos necesarios

    Geriátrika: Revista iberoamericana de geriatría y gerontología, Vol. 19, Núm. 9, pp. 19-25

  2. La medición de la capacidad funcional en el mayor desde la perspectiva de los apoyos necesarios

    Geriatrika, Vol. 19, Núm. 9-10, pp. 19-25

  3. Positive effects of Cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: An exploratory study

    International Clinical Psychopharmacology, Vol. 18, Núm. 5, pp. 271-278

2002

  1. Alteraciones conductuales en un enfermo de Alzheimer

    Geriatrika, Vol. 18, Núm. 1, pp. 40-44

2001

  1. Calidad de Vida y Salud

    Revista multidisciplinar de gerontología, Vol. 11, Núm. 1, pp. 12-19

  2. Calidad de vida y diferencias en función del sexo

    Revista multidisciplinar de gerontología, Vol. 11, Núm. 4, pp. 173-180

  3. La dependencia en España. Un análisis cuantitativo

    Geriatrika, Vol. 17, Núm. 2, pp. 25-32